Because lithium exerts neuroprotective effects in preclinical models of polyglutamine disorders , our objective was to assess the safety and efficacy of lithium carbonate ( 0.5-0 .8 milliequivalents per liter ) in patients with Machado-Joseph disease ( spinocerebellar ataxia type 3 [ MJD/SCA3 ] ) .